छोड़कर सामग्री पर जाएँ

AstraZeneca Pharma rises 4% on getting CDSCO nod to import cancer treatment drug

AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.

Top 100 Best Sellers

Read More

​ AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period. AstraZeneca Pharma stock has risen 57 percent in the last one year, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी
en_USEnglish hi_INहिन्दी